Swedish biopharmaceutical company Alzinova received FDA clearance to begin Phase II clinical trials of ALZ-101, a vaccine targeting toxic amyloid-beta oligomers in Alzheimer’s disease. Following encouraging Phase Ib safety and immunogenicity data, ALZ-101 aims to stimulate antibodies against oligomers considered critical in disease progression. This IND approval enables expanded testing in a larger patient population, marking a key milestone in Alzheimer’s therapeutic development.